Search - tctmd.com

Displaying 21 - 40 of 45

Sort: Relevancy | Date

Presentation ACC 2025

The MIGHTy-Heart Randomized Clinical Trial

Presenter: Ruth Masterson Creber

March 30, 2025

Presentation ACC 2025

FAIR-HF2 Trial: Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality

Presenter: Stefan D. Anker

March 30, 2025

Presentation ACC 2025

Liberal Fluid Intake versus Fluid Restriction in Chronic Heart Failure: The FRESH-UP Study

Presenter: Roland R. Van Kimmenade

March 30, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Presentation ACC 2025

STRIDE - Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes

Presenter: Marc P. Bonaca

March 29, 2025

Presentation ACC 2025

Dapagliflozin after Transcatheter Aortic Valve Implantation

Presenter: Sergio Raposeiras-Roubin

March 29, 2025

Presentation ACC 2025

Advance-HTN: Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension

Presenter: Luke Laffin

March 29, 2025

Presentation ACC 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Presenter: Darren K. McGuire

March 29, 2025

News Daily News ACC 2025

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

L.A. McKeown

March 29, 2025

Presentation ACC 2025

Clopidogrel versus Aspirin Monotherapy in Patients with High Ischemic Risk after PCI: SMART-CHOICE 3 Trial

Presenter: Joo-Yong Hahn

March 29, 2025

Presentation ACC 2025

Dual Antiplatelet Therapy After PCI According To Bleeding Risk: HOST-BR RCT

Presenter: Hyo-Soo Kim

March 29, 2025

Presentation ACC 2025

Four-Factor Prothrombin Complex Concentrate is Superior to Frozen Plasma in Bleeding Adult Cardiac Surgery Patients with Coagulopathy—Results from a Phase 3, Randomized, Active-Control Study

Presenter: Keyvan Karkouti

March 29, 2025

News Conference News ACC 2025

WARRIOR: No Clear Answers on How to Best Treat INOCA

Yael L. Maxwell

March 29, 2025

Presentation ACC 2025

Extended Anticoagulant Treatment With A Reduced Versus Full Dose Apixaban In Patients With Cancer-associated Venous Thromboembolism: The API-CAT Study

Presenter: Isabelle Mahé

March 29, 2025

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

Caitlin E. Cox

March 29, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

Video

» Interview

Beyond the Data: The ALIGN-AR Trial

April 18, 2025

Video

» Interview

Beyond the Data: The SOUL Trial

April 4, 2025

Video

» Interview

ACC 2025 Conference Wrap-Up

April 2, 2025

Video

» Interview

ACC 2025 Day 3 Wrap-Up

March 31, 2025

Advertisement

The MIGHTy-Heart Randomized Clinical Trial

FAIR-HF2 Trial: Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality

Liberal Fluid Intake versus Fluid Restriction in Chronic Heart Failure: The FRESH-UP Study

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

STRIDE - Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes

Dapagliflozin after Transcatheter Aortic Valve Implantation

Advance-HTN: Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

Clopidogrel versus Aspirin Monotherapy in Patients with High Ischemic Risk after PCI: SMART-CHOICE 3 Trial

Dual Antiplatelet Therapy After PCI According To Bleeding Risk: HOST-BR RCT

Four-Factor Prothrombin Complex Concentrate is Superior to Frozen Plasma in Bleeding Adult Cardiac Surgery Patients with Coagulopathy—Results from a Phase 3, Randomized, Active-Control Study

WARRIOR: No Clear Answers on How to Best Treat INOCA

Extended Anticoagulant Treatment With A Reduced Versus Full Dose Apixaban In Patients With Cancer-associated Venous Thromboembolism: The API-CAT Study

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

What’s Going to Be Hot at ACC 2025?

Beyond the Data: The ALIGN-AR Trial

Beyond the Data: The SOUL Trial

ACC 2025 Conference Wrap-Up

ACC 2025 Day 3 Wrap-Up

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content